Scarica l'app Stockscreener
0.79
2.52%
-0.0204
Precedente Chiudi:
$0.8104
Aprire:
$0.81
Volume 24 ore:
137.29K
Relative Volume:
0.10
Capitalizzazione di mercato:
$4.64M
Reddito:
-
Utile/perdita netta:
$-11.27M
Rapporto P/E:
-0.0369
EPS:
-21.4132
Flusso di cassa netto:
$-9.40M
1 W Prestazione:
-7.60%
1M Prestazione:
-2.23%
6M Prestazione:
-38.76%
1 anno Prestazione:
-85.32%
Intervallo 1D:
$0.75
$0.82
Intervallo di 1 settimana:
$0.75
$0.9899
Portata 52W:
$0.69
$5.85
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Nome
Dermata Therapeutics Inc
Settore
Industria
Telefono
(858)-223-0882
Indirizzo
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Confronta DRMA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
0.79 | 4.64M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.99 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.48 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
556.41 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.90 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
227.66 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Dermata Therapeutics Inc Borsa (DRMA) Ultime notizie
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
DRMAWDermata Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Dermata Therapeutics stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa
Dermata Therapeutics stock hits 52-week low at $0.7 - Investing.com Australia
Dermata reports early success in acne treatment with XYNGARI By Investing.com - Investing.com South Africa
Dermata Therapeutics (DRMA) Reports Promising Phase 3 Trial Resu - GuruFocus
Dermata Therapeutics IncAnnounces Topline Results From Phase 3 Trial Of XyngariSEC Filing - marketscreener.com
Dermata reports early success in acne treatment with XYNGARI - Investing.com
First-Ever Weekly Acne Treatment XYNGARI Achieves Major Phase 3 Success - Stock Titan
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 307.9% in March - Defense World
Dermata Therapeutics stock hits 52-week low at $0.79 By Investing.com - Investing.com Canada
Dermata Therapeutics stock hits 52-week low at $0.79 - Investing.com
Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com
Dermata Therapeutics stock hits 52-week low at $1 - Investing.com
Dermata (DRMA) Initiates Warrant Exercise to Raise $6.2 Million - GuruFocus
Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Dermata Therapeutics (NASDAQ:DRMA) Shares Up 5.2% – Here’s What Happened - Defense World
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement - Stock Titan
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Benzinga
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains - Stocks Telegraph
XYNGARI shows promise in Phase 3 acne trial By Investing.com - Investing.com South Africa
Dermata shares rise on positive acne treatment trial results By Investing.com - Investing.com South Africa
Dermata shares rise on positive acne treatment trial results - Investing.com
Dermata's XYNGARI(TM) Phase 3 Trial Topline Data Meets All Primary Endpoints - MarketScreener
XYNGARI shows promise in Phase 3 acne trial - Investing.com
First-Ever Weekly Acne Treatment XYNGARI Achieves Breakthrough in Phase 3 Trial - Stock Titan
Dermata Therapeutics Faces Nasdaq Delisting Notice By Investing.com - Investing.com India
Dermata Therapeutics Faces Nasdaq Delisting Notice - Investing.com
Dermata Therapeutics, Inc. SEC 10-K Report - TradingView
Major Catalyst Alert: Dermata's Phase 3 Acne Treatment Results Coming in Weeks - StockTitan
Stocks Rally as US Consumer Prices Cool - The Globe and Mail
Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart
Acne Market on Track for Major Expansion by 2032, According - openPR
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne - openPR
Tesla Stock is OversoldIs Now the Time to Be Brave? - The Globe and Mail
Head-To-Head Analysis: Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) - The AM Reporter
Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) Head-To-Head Comparison - Defense World
Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne - Marketscreener.com
Dermata Therapeutics announces last patient visit in Phase 3 acne trial - TipRanks
Dermata Therapeutics Inc Azioni (DRMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):